| Endogenous bradykinin suppresses myocardial fibrosis through the cardiac-generated endothelin system under chronic angiotensin-converting enzyme inhibition in heart failure. | |
| | |
MedLine Citation:
|
PMID: 15838317 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In congestive heart failure, angiotensin-converting enzyme inhibitors (ACEIs) may prevent cardiac fibrosis via interaction with both angiotensin II and endothelin-1, which enhance myocardial collagen synthesis. However, whether endogenous bradykinin with an ACEI modifies the cardiac collagen architecture, affecting the endothelin system, has not yet been fully elucidated. We evaluated the changes in circulating hormonal factors, myocardial fibrosis and cardiac gene expression closely linked with heart failure, using an orally active specific bradykinin type 2 receptor antagonist, FR173657 (0.3 mg/kg/day, n = 6), with an ACEI, enalapril (1 mg/kg/day), in dogs with tachycardia-induced congestive heart failure (270 p.p.m., 22 days) and compared the effects with enalapril alone (n = 6). Although there were no differences observed in blood pressure, plasma renin activity, aldosterone and endothelin-1 levels, combined FR173657 significantly increased the cardiac expression of preproendothelin- 1 mRNA (P < 0.05) and collagen type I and type III mRNA (P < 0.05), and cardiac collagen deposits (P < 0.05), and decreased eNOS gene expression (P < 0.05) in the left ventricle compared with the ACEI-treated group. Furthermore, there was a significant negative correlation between the expression of preproendothelin- 1 and eNOS mRNA levels (r = -0.708, P < 0.001). In conclusion, bradykinin may prevent cardiac fibrosis in part via suppression of the local endothelin system in the failing heart through the enhancement of nitric oxide production under chronic angiotensin-converting enzyme inhibition. |
| | |
Authors:
|
Masanori Fujii; Atsuyuki Wada; Masato Ohnishi; Takayoshi Tsutamoto; Takehiro Matsumoto; Takashi Yamamoto; Tomoyuki Takayama; Tomohiro Dohke; Takahiro Isono; Yutaka Eguchi; Minoru Horie |
Related Documents
:
|
11309257 - Role of nitric oxide synthases in the infarct size-reducing effect conferred by heat st... 18762777 - Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarc... 8753677 - Myocardial infarction in rats: high-resolution single-photon emission tomographic imagi... 8800587 - Validation of an echocardiographic assessment of cardiac function following moderate si... 11714997 - Elevated interleukin-1beta in pericardial fluid of patients with ischemic heart disease. 16531917 - Evaluation of left ventricular ejection fraction by the quantitative algorithms qgs, ec... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of cardiovascular pharmacology Volume: 44 Suppl 1 ISSN: 1533-4023 ISO Abbreviation: J. Cardiovasc. Pharmacol. Publication Date: 2004 Nov |
Date Detail:
|
Created Date: 2005-04-19 Completed Date: 2008-11-03 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 7902492 Medline TA: J Cardiovasc Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: S346-9 Citation Subset: IM |
Affiliation:
|
Intensive Care Unit, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
blood Angiotensin-Converting Enzyme Inhibitors / pharmacology* Animals Bradykinin / metabolism* Collagen / genetics, metabolism* Disease Models, Animal Dogs Enalapril / pharmacology* Endothelin-1 / genetics, metabolism* Fibrosis Heart Failure / drug therapy*, metabolism, pathology, physiopathology Hemodynamics / drug effects Myocardium / enzymology, metabolism*, pathology Nitric Oxide / metabolism Nitric Oxide Synthase Type II / metabolism Nitric Oxide Synthase Type III Quinolines / pharmacology RNA, Messenger / metabolism Receptor, Bradykinin B2 / antagonists & inhibitors, metabolism Renin / blood |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Endothelin-1; 0/FR 173657; 0/Quinolines; 0/RNA, Messenger; 0/Receptor, Bradykinin B2; 10102-43-9/Nitric Oxide; 52-39-1/Aldosterone; 58-82-2/Bradykinin; 75847-73-3/Enalapril; 9007-34-5/Collagen; EC 1.14.13.39/Nitric Oxide Synthase Type II; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos3 protein, rat; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Differential changes in endothelin-1 and endothelial nitric oxide synthase gene expression in rats w...
Next Document: The functional shift of endothelin receptor subtypes in dogs with heart failure produced by rapid ve...